|
The enhanced bioavailability of tamoxifen by curcumin may be mainly due to inhibition of the CYP3A4 mediated metabolism of tamoxifen in the small intestine and or in the liver and to inhibition of the P gp efflux transporter in the small intestine rather than to reduction of renal elimination of tamoxifen, suggesting that curcumin may reduce the first pass metabolism of tamoxifen in the small intestine and or in the liver by inhibition of P gp or CYP3A4 subfamily <a href=https://lasix2buy.top/>lasix no prescription</a> CALGB 9840 phase III study of weekly W paclitaxel P via 1 hour infusion versus standard S 3h infusion every third week in the treatment of metastatic breast cancer MBC, with trastuzumab T for HER2 positive MBC and randomized for T in HER2 normal MBC |
|